International Journal of Preventive Medicine (Int J Prev Med)2008-78021120120414902910ENDepartment of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi-5, Uttar Pradesh, IndiaPharmacology, Prathima Institute of Medical Sciences, Nagunur, Karimnagar, Andhra Pradesh, IndiaDepartment of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi-5, Uttar Pradesh, IndiaGeneral Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi‑5, Uttar Pradesh,, IndiaNephrology, Institute of Medical Sciences, Banaras Hindu University, Varanasi‑5, Uttar Pradesh, IndiaDepartment of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi-5, Uttar Pradesh, India20120414<p><strong>Background: </strong>Chronic kidney disease (CKD) coexisting with type 2 diabetes mellitus (DM) leads to coronary artery disease. The present study compares clopidogrel and low‑dose aspirin as prophylactic therapy against coronary events in patients with CKD with diabetes.</p> <p><strong>Methods: </strong>Total 80 patients of CKD with type 2 DM were randomized and allocated to clopidogrel and aspirin groups to receive the drug at a dose of 75 mg and 150 mg once daily respectively for 8 weeks as add‑on therapy. Main outcome was change in blood pressure, metabolic parameters, renal function, inflammatory biomarkers, platelet aggregability and UKPDS risk scoring.</p> <p><strong>Results: </strong>Significant decrease in blood pressure (<em>P </em>&lt; 0.01), total cholesterol (<em>P </em>= 0.02), LDL (<em>P </em>&lt; 0.01), triglyceride (<em>P </em>&lt; 0.01) and a better glycemic control (<em>P </em>&lt; 0.01) was found in clopidogrel group. Renal markers and electrolytes have been improved in clopidogrel group but in aspirin group there was deterioration (2.5%) of creatinine clearance. Clopidogrel group has shown a significant decrease in hsCRP (<em>P </em>&lt; 0.01), UKPDS risk scoring (<em>P </em>&lt; 0.01) and better anti‑aggregatory effect.</p> <p><strong>Conclusions: </strong>Clopidogrel has prophylactic role in CKD with type 2 DM due to better control of metabolic parameters, renal function and inflammatory burden in comparison to aspirin.</p> <strong>Keywords: </strong>Chronic kidney disease, clopidogrel, low‑dose aspirin, type 2 diabetes mellitushttp://ijpm.mui.ac.ir/index.php/ijpm/article/view/657http://ijpm.mui.ac.ir/index.php/ijpm/article/download/657/1099